DEXCOM INC (DXCM)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Open DEXCOM INC in the interactive graph- Ticker
- DXCM
- SEC CIK
- 0001093557
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Periods
- FY2025 Q1, FY2025 Q4, FY2026, FY2026 Q1, FY2026 Q3, FY2027
- Headquarters
- San Diego, CA
- Employees
- 11,000
Key figures
- Revenue 359.60M USD
- NetIncome 199.50M USD
- DilutedEPS 0.51 USD/share
Reported figures
- BasicEPS 0.27 USD/share
- BasicEPS 0.52 USD/share
- BasicSharesOutstanding 385.10M count
- BasicSharesOutstanding 391.10M count
- CapitalExpenditure 76.60M USD
- CashAndEquivalents 1.12B USD
- CashAndEquivalents 917.70M USD
- CostOfRevenue 441.60M USD
- CostOfRevenue 447.00M USD
- DilutedEPS 0.27 USD/share
- DilutedEPS 0.32 USD/share
- DilutedEPS 0.51 USD/share
- DilutedEPS 0.56 USD/share
- EBITDA 230.40M USD
- EBITDA 364.50M USD
- FreeCashFlow 449.00M USD
- GrossMargin 56.9 percent
- GrossMargin 57.5 percent
- GrossMargin 62.9 percent
- GrossMargin 63.5 percent
- GrossProfit 589.00M USD
- GrossProfit 596.20M USD
- GrossProfit 750.30M USD
- GrossProfit 757.40M USD
- InterestExpense 3.10M USD
- NetIncome 105.40M USD
- NetIncome 127.70M USD
- NetIncome 199.50M USD
- NetIncome 216.30M USD
- OperatingExpenses 455.30M USD
- OperatingExpenses 495.00M USD
- OperatingIncome 133.70M USD
- OperatingIncome 143.10M USD
- OperatingIncome 255.30M USD
- OperatingIncome 264.40M USD
- OperatingMargin 12.9 percent
- OperatingMargin 13.8 percent
- OperatingMargin 21.4 percent
- OperatingMargin 22.2 percent
- OtherMetric 1.08B USD
- and 24 more in the interactive graph
Guidance
- EBITDAMargin guidance 31–31.5 percent
- GrossMargin guidance 63–64 percent
- OperatingMargin guidance 23–23.5 percent
- Revenue guidance 5.16B–5.25B USD
Drivers
- Healthy demand for Dexcom CGM contributed to strong revenue growth
Quotes
- “Dexcom delivered strong revenue growth and margin performance to start the year,…”
- “We will work to build on this momentum throughout 2026 and look forward to highl…”